The relationship between antihypertensive combination therapies comprising diuretics and/or β-blockers and the risk of new-onset diabetes: A retrospective longitudinal cohort study

Hypertension Research

Volumn 32, Issue 6, 2009, Pages 496-499

  Liou, Yi Sheng ^a   Ma, Tsochiang ^b   Tien, Liyun ^c   Lin, Chieh Min ^b   Jong, Gwo Ping ^d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Bureau of National Health Insurance Taiwan   (Taiwan)

^d CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; SEX FACTORS; TAIWAN;

EID: 68249140070     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.45     Document Type: Article

References (24)

1. Iseki K, Oshiro S, Tozawa M, Ikemiya Y, Fukiyama K, Takishita S. Prevalence and correlates of diabetes mellitus in a screened cohort in Okinawa, Japan. Hypertens Res 2002; 25: 185-190.
2. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, Fujitani Y, Hirose T, Kawamori R. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13.
3. Rajala U, Qiao Q, Laakso M, Keinänen-Kiukaanniemi S. Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2000; 50: 231-239.
4. Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003; 26: 453-458.
5. Kudoh T, Nagawaga T, Nakagawa I. Additional small amounts of diuretics improve blood pressure control at low cost without disadvantages in blood sugar metabolism. Hypertens Res 2008; 31: 455-462.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
7. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk Factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 2000; 342: 905-912.
8. Elliott WJ. Differential effects of antihypertensive drugs on new-onset diabetes? Curr Hypertens Report 2005; 7: 249-256.
9. Campbell NR, McAlister FA, Duong-Hua M, Tu K. Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement. Can J Cardiol 2007; 23: 783-787.
10. Saito I, Kobayashi M, Matsushita Y, Mori A, Kawasugi K, Saruta T. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res 2008; 31: 455-462.
11. Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: Are they all the same? Am J Cardiovas Drug 2007; 7: 413-422.
12. Padwal R, Laupacis A. Antihypertensive Therapy and incidence of type 2 diabetes: A systematic review. Diabetes Care 2004; 27: 247-255.
13. Padwal R, Mamdani M, Alter DA, Hux JE, Rothwell DM, Tu K, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004; 27: 2458-2463.
14. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J, The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial. Diabetologia 2004; 47: 1519-1527.
15. Lithell HO. Hyperinsulinemia, insulin resistance, and treatment of hypertension. Am J hypertens 1996; 9: 150S-154S.
16. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-616.
17. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
18. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in eldery patients: Cardiovascular mortality and morbidity the Swedish trial on old patients with hypertension-2 study. Lancet 1999; 354: 1751-1756.
19. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006; 29: 1065-1070.
20. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006; 6: 796-806.
21. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
22. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-2597.
23. Israili ZH, Lyoussi B, HernAjndez-HernAjndez R, Velasco M. Metabolic syndrome: Treatment of hypertensive patients. Am J Ther 2007; 14: 386-402.
24. Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepi Drug Saf 2007; 16: 979-987.